[ad_1]
Synopsis
The deal improves the value proposition of Biocon Biologics by providing a better cash flow outlook and broadened portfolio ahead of the company’s plan to go for an IPO in the next two to three years. While the deal offers Biocon Biologics a perch in a new business, Serum Institute gets a chance to test the waters beyond vaccines.
India’s leading entrepreneurs Kiran Mazumdar-Shaw and Adar Poonawalla struck an unusual but interesting deal last week. Biocon Biologics, the biosimilars arm of Mazumdar-Shaw’s company Biocon, entered into a strategic alliance with Serum Institute Life Sciences Pvt Ltd, a subsidiary of Poonawalla’s Serum Institute of India, to make a foray into vaccines. According to the deal, Biocon Biologics will get access to 100 million doses of vaccines per
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link